Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...
The American Journal of Managed Care10h
FDA Approves Mirdametinib for Neurofibromatosis Type 1 with Plexiform Neurofibromas
Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...
STAT11h
Pharmalittle: We’re reading about pharma silence on Trump moves, lawmakers eyeing PBMs again, and more
A U.S. judge ordered federal agencies to restore access to health-related webpages and datasets removed by the Trump ...
Pharmaceutical Technology on MSN13h
FDA approves Gomekli as first neurofibromatosis drug for adults
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
American Academy of Dermatology3h
2025 quality measures for MIPS reporting
Percentage of biopsies with a diagnosis of cutaneous Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), or melanoma (including in situ disease) in which the pathologist communicates results ...
Federal health agencies restore webpages and datasets following judge’s order
Federal health agencies have restored several webpages and datasets, following a judge’s order to bring back public access to ...
The American Journal of Managed Care4h
Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval
The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...